ArticleJournal of nanobiotechnology2026
ROS-responsive Ganoderma lucidum polysaccharide nanocomposite targeting prosenescent oxidative stress niche for structural and functional diabetic tendon regeneration.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Oxidative Stress for Precision Therapy: Reactive Oxygen Species-Responsive Hydrogel-Nanocarrier Systems as Translational Redox Drug-Delivery Platforms.ACS pharmacology & translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Diabetic patients exhibit higher tendon injury incidence, with elevated risks of healing failure and re-rupture than healthy individuals, posing major clinical challenges. Tendon stem/progenitor cells (TSPCs) are crucial for tendon homeostasis maintenance, and their senescence underlies regenerative impairment. In this study, diabetic rat Achilles tendon-derived TSPCs (dTSPCs) were identified to exhibit accelerated cellular senescence and dysfunction. Mechanistically, the excessive activation of the Ras/MAPK axis, which mediates mitochondrial dysregulation and elevated reactive oxygen species (ROS) production, was a key driver of dTSPCs senescence and impaired diabetic tendon regenerative capacity. Accordingly, we developed a nanocomposite hydrogel system loaded with Ganoderma lucidum polysaccharides (GLPs), consists of a ROS-responsive PVA-TSPBA hydrogel encapsulating GLPs@ZIF-8 nanoparticles (GZPT). In vitro, GZPT effectively suppressed Ca²⁺ influx, thereby inhibiting aberrant Ras/MAPK axis activation mediated mitochondrial dysfunction and ROS overproduction, ultimately attenuating dTSPCs senescence and dysfunction. In vivo, GZPT enables sustained and precisely controlled release of GLPs, promoting structural regeneration and functional restoration of diabetic tendon defects by mitigating the prosenescent oxidative stress niche. These findings demonstrate that GZPT effectively enhances the functionality of senescent dTSPCs and facilitates diabetic tendon regeneration, suggesting that GZPT represents a promising clinical strategy for improving tendon structural and functional regeneration in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.